

Welcome to today's FDA/CDRH Webinar

Thank you for your patience while additional time is provided for participants to join the call.

If you have not connected to the audio portion of the webinar, please do so now:

US Callers Dial: 1-888-469-0942;

International Callers Dial: 1-312-470-7421

Passcode: 4879169



Special 510(k) Program Pilot

Angela DeMarco
510(k) Staff
Office of Device Evaluation

Joshua Silverstein
Regulatory Advisor
Office of Device Evaluation

Center for Devices and Radiological Health



Agenda

This presentation will cover:

- Purpose of the Special 510(k) Program pilot
- Background
- Differences between the Program pilot and the existing Program
- Effect on current review of Special 510(k) submissions



Objectives

After this training, you should know:

- How to determine whether your submission is appropriate for the Special 510(k) Program pilot using the updated eligibility factors
- What to expect from the review process



Purpose of the Special 510(k) Program Pilot

The purpose of the Special 510(k) Program Pilot is to:

 Determine whether updated factors for eligibility in the Special 510(k) Program will improve FDA staff's efficiency in reviewing 510(k) submissions



Background

- The New 510(k) Paradigm guidance established the
 - Special 510(k) program in 1998
- Summary of the Special 510(k) program:
 - Leverages design controls and previously submitted information so that FDA can do a summary-level review for certain 510(k)s in 30 days
 - Does not alter the requirements for premarket notification under sections 510 and 513 of the Federal Food, Drug, and Cosmetic Act and 21 CFR 807 Subpart E

New 510(k) Paradigm

Alternate Approaches to Demonstrating Substantial Equivalence in Premarket Notifications

This document is intended to provide guidance. It represents the Agency's current thinking on the above. It does not create or confer any rights for or on any person and does not operate so bind FDA acover, a cores not create or countri any agains not on any person and ones not operate to onat race or the public. An alternative approach may be used if such approach satisfies the requirements of the

> Prepared by the Center for Devices and Radiological Health

> > March 20, 1998

Comments and suggestions may be submitted at any time for Agency consideration to Heather Rosecrans, Office of Device Evaluation, 10903 New Hampshire Avenue, Silver Spring, MD 20993. Comments may not be acted upon by the Agency until the document is next revised or updated. For questions regarding the use or interpretation of this guidance, contact the Premarket Nonfication (510(k)) Section at 301-796-5640.

For additional copies: World Wide Web/CDRH home page: http://www.fda.gov/cdrh. You may also send an e-mail request to dismica@fda hhs gov to receive an electronic copy of the guidance or send a

U.S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Center for Devices and Radiological Health



What Prompted this Pilot?

The FDA periodically pilots programs to help improve consistency and efficiency in 510(k) review, and help reduce total time to decision.

- MDUFA IV shared outcome goals include decreasing 510(k) total time to decision to 108 days by fiscal year 2022
- Special 510(k) updates are part of CDRH's plan to reduce total time to decision
- The FDA intends to process Special 510(k)s in 30 days, rather than the 90 days required by section 510(n)(1) of the Federal Food, Drug, and Cosmetic Act



Scope

- This pilot includes all 510(k) submissions received on or after October 1, 2018 that are identified and eligible for review as a Special 510(k)
- This pilot does not include submissions reviewed by the Center for Biologics Evaluation and Research (CBER)





Changes Being Piloted

Remains the same:


The proposed change is made and submitted by the manufacturer authorized to market the existing device

1998 Final Guidance	Special 510(k) Program Pilot
Changes(s) do not affect intended use; and	Performance data are unnecessary, or if performance data are necessary, well-established methods are available to evaluate the change; and
Change(s) do not alter the fundamental scientific technology	All data necessary to support substantial equivalence can be reviewed in a summary or risk analysis format



For the purposes of this flowchart, the FDA assumes the manufacturer has made a change that requires a 510(k) per 21 CFR 807.81(a)(3)

Note: Flowcharts are provided as a visual aid, but do not capture all necessary considerations





Eligibility Factors

- The proposed change is made and submitted by the manufacturer authorized to market the existing device, and
- Performance data are unnecessary, or if performance data are necessary, well-established methods are available to evaluate the change, and
- All performance data necessary to support substantial equivalence can be reviewed in a summary or risk analysis format



Is it a change to the manufacturer's own device?

No change from existing Special 510(k) policy.

- Special 510(k) leverages information already submitted to the FDA and existing design controls procedures
- The predicate device should be the manufacturer's own device



Is testing needed to evaluate the change? (indications for use, labeling or technology)

- Moving away from automatic conversions for nonclerical changes to the indications for use
- If testing is not necessary, appropriate for a Special 510(k)
- If testing is necessary, proceed to the next question



Is there a well-established method to evaluate the change?

- Well established methods:
 - Those used in the previously-cleared 510(k)
 - Methods in an FDA recognized consensus standard
 - Widely available and accepted methods published in the public domain, scientific literature, or found acceptable by the FDA
- All methods used in subject 510(k) should be wellestablished
- If there is not a well-established method, the FDA intends to convert the submission to a Traditional 510(k)



Can the data be reviewed in a summary or risk analysis format?

No change from existing Special 510(k) policy.

- Complete test reports should not be submitted in a Special 510(k)
- The FDA intends to assess whether information can be summarized, but will convert the submission to a Traditional 510(k) as necessary
- Data cannot be summarized when substantial equivalence determination depends on the FDA's interpretation of the underlying data, such as images, raw graphs, or line item data.
 Small numbers of representative images can be submitted



When a Special 510(k) may not be appropriate:

- Changes that involve several different scientific review disciplines
- Multiple devices with unrelated changes
- Common scenarios when a complete test report will be necessary to establish substantial equivalence (clinical data, novel sterilization methods, certain Magnetic Resonance compatibility labeling changes, when validation data should be provided (human factors, reprocessing), chemical characterization for biocompatibility)
- When validation data is required for reprocessed singleuse devices and reusable devices identified in Federal Register notices

Preparing the 510(k)



- The following best practices still apply for Special 510(k) submission preparation:
 - Tabular summary of design control activities
 - Summary or table listing changes, which could include redlined versions of previously submitted information
- See the FDA guidance <u>Frequently Asked Questions on the New 510(k) Paradigm</u> and <u>How to Prepare a Special</u>
 510(k) webpage for an example and more information



Submitting the 510(k)

No change from current method

- Send by mail to CDRH's Document Control Center
- Valid <u>eCopy</u> required
 - Hard copy duplicate not needed
 - Include a hard copy of the cover letter
- MDUFA User Fees apply



Review Process

No impact on substantive or scientific review

- Pilot Refuse to Accept (RTA) form has pilot eligibility factors on page 1
- The Elements of a Complete Submission (Refuse to Accept items) have not changed
- The FDA intends to process Special 510(k)s in 30 days
 - The review should be <u>interactive</u>
 - The FDA may request additional information through an email with an attached document identifying deficiencies when warranted





- The Special 510(k) will be converted to a Traditional 510(k)
- Same concurrence process for conversions as existing program
- The FDA will email the official contact of the 510(k) to state the reason for conversion



Pilot Assessment

The FDA will collect the following:

- Number of Special 510(k) submissions received
- 510(k) number
- The FDA Day it was placed on hold, if applicable
- Total time to decision
- If a submission was found not appropriate for a Special 510(k):
 - The reason
 - The FDA Day on which it was concurred upon as inappropriate
 - Total number of submissions that were converted from Special 510(k) to Traditional 510(k)



Stakeholder Considerations

- The pilot began October 1, 2018
- All 510(k) submissions marked and eligible as a Special 510(k) will be considered for the pilot program
 - No additional designation is necessary



Benefits

- Expand on the types of changes eligible for the Special 510(k) program
- Improve the efficiency of 510(k) review
- Decrease total time to decision for 510(k) submissions to meet MDUFA shared outcome goals
- Promote timely access to safe, effective, and highquality medical devices



Resources

- 510(k) Program Pilot webpage <u>https://www.fda.gov/MedicalDevices/DeviceRegulationand</u> <u>Guidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketNotification510k/ucm618561.htm</u>
- Frequently Asked Questions on The New 510(k) Paradigm https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm073946.htm



Questions?

For Questions Specific to the 510 Program, email: 510k_Program@fda.hhs.gov

For General Questions, email: Division of Industry and Consumer Education: DICE@fda.hhs.gov

Slide Presentation, Transcript and Webinar Recording will be available at:

http://www.fda.gov/training/cdrhlearn

Under Heading: How to Study and Market Your Device; Subheading: Premarket Notification 510 (K)

Please complete a short survey about your FDA CDRH webinar experience. The survey can be found at www.fda.gov/CDRHWebinar immediately following the conclusion of the live webinar.